Cargando…

Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients

DMD is a rare disorder characterized by progressive muscle degeneration and premature death. Therapy development is delayed by difficulties to monitor efficacy non‐invasively in clinical trials. In this study, we used RNA‐sequencing to describe the pathophysiological changes in skeletal muscle of 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signorelli, Mirko, Ebrahimpoor, Mitra, Veth, Olga, Hettne, Kristina, Verwey, Nisha, García‐Rodríguez, Raquel, Tanganyika‐deWinter, Christa L, Lopez Hernandez, Luz B, Escobar Cedillo, Rosa, Gómez Díaz, Benjamín, Magnusson, Olafur T, Mei, Hailiang, Tsonaka, Roula, Aartsma‐Rus, Annemieke, Spitali, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033515/ https://www.ncbi.nlm.nih.gov/pubmed/33751844 http://dx.doi.org/10.15252/emmm.202013328

Ejemplares similares

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Simultaneous Enrichment Analysis of all Possible Gene-sets: Unifying Self-Contained and Competitive Methods
por: Ebrahimpoor, Mitra, et al.
Publicado: (2019)

Plasma lipidomic analysis shows a disease progression signature in mdx mice
por: Tsonaka, Roula, et al.
Publicado: (2021)

Pathway testing for longitudinal metabolomics
por: Ebrahimpoor, Mitra, et al.
Publicado: (2021)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Cross‐sectional serum metabolomic study of multiple forms of muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2018)

Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinal and high‐dimensional data
por: Signorelli, Mirko, et al.
Publicado: (2021)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Negative Binomial mixed models estimated with the maximum likelihood method can be used for longitudinal RNAseq data
por: Tsonaka, Roula, et al.
Publicado: (2020)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice
por: Spitali, Pietro, et al.
Publicado: (2013)

The mRNA Binding Proteome of Proliferating and Differentiated Muscle Cells
por: Hiller, Monika, et al.
Publicado: (2020)

Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
por: Jirka, Silvana M.G., et al.
Publicado: (2018)

SplicePie: a novel analytical approach for the detection of alternative, non-sequential and recursive splicing
por: Pulyakhina, Irina, et al.
Publicado: (2015)

SplicePie: a novel analytical approach for the detection of alternative, non-sequential and recursive splicing
por: Pulyakhina, Irina, et al.
Publicado: (2015)

Non-sequential and multi-step splicing of the dystrophin transcript
por: Gazzoli, Isabella, et al.
Publicado: (2015)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
por: Bizot, Flavien, et al.
Publicado: (2022)

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E.C., et al.
Publicado: (2021)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
por: van Westering, Tirsa L.E., et al.
Publicado: (2019)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

The use of genetically humanized animal models for personalized medicine approaches
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
por: Heezen, L.G.M., et al.
Publicado: (2023)

Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine(ratio), and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy
por: van de Velde, Nienke M., et al.
Publicado: (2023)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Splicing modulation therapy in the treatment of genetic diseases
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2014)

The Role of Patient Involvement When Developing Therapies
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2022)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Measuring DNA hybridization using fluorescent DNA-stabilized silver clusters to investigate mismatch effects on therapeutic oligonucleotides
por: de Bruin, Donny, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9ar48moaig6t7sqt6tn8ae27fp